OCGN · Ocugen, Inc. · Insider Trading

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4.

The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.11 to $1.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4.

The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.06 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4.

The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option, representing a right to purchase 112,205 shares, vested and became exercisable on June 9, 2024.

The option, initially representing a right to purchase 54,000 shares, vested and became exercisable in equal installments over three years commencing on January 2, 2020.

The option, representing a right to purchase 66,929 shares, vested and became exercisable on June 28, 2025.

The option vests annually in equal installments over three years commencing on January 2, 2027, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2027, subject to continued service with the Issuer on the applicable vesting dates.

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest annually in three equal installments commencing on January 2, 2027, subject to continued service with the Issuer on the applicable vesting dates.

Reflects a grant of performance stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain performance goals, subject to continued service with the Issuer on the applicable vesting dates.

The option vests monthly in equal installments over three years commencing on July 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 5, 2026 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 5, 2026 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests monthly in equal installments over three years commencing on July 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 5, 2026 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9042 to $0.9145. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9138 to $0.9139. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests annually in equal installments over three years commencing on April 16, 2025, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2025, subject to continued service with the Issuer on the applicable vesting dates.

The option vests annually in equal installments over three years commencing on January 2, 2025, subject to continued service with the Issuer on the applicable vesting dates.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4993 to $0.5034. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.